• Growth factor therapy based on a confirmed deficiency or inappropriate production of cells or growth factors in a demand-situation (eg, injection of erythropoietin as comedication in patients with low endogenous erythropoietin in hematologic neoplasms). Here, EPO is linked to hematopoietic and lymphoid system neoplasm.